The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000809336p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
18/05/2026
Date registered
Help: Date registered
7/07/2026
Date last updated
Help: Date last updated
11/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/07/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
An open-label, first-in-human, dose escalation study to determine the pharmacokinetics, pharmacodynamics, tolerability and safety of BYT-1007 in patients with hematologic malignancies
Scientific title
An open-label, first-in-human, dose escalation study to determine the pharmacokinetics, pharmacodynamics, tolerability and safety of BYT-1007 in patients with hematologic malignancies
Additional trial identifiers [1] 317308 0
BY103CS01
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Hematologic Malignancies 341943 0
Condition category
Condition code
Cancer 338005 338005 0 0
Leukaemia - Acute leukaemia

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Part A (BYT-1007 monotherapy)
Participants will be enrolled sequentially into escalating dose cohorts. Dose levels will be assessed sequentially rather than concurrently. After all participants within a dose cohort complete Cycle 1 (the dose-limiting toxicity [DLT] evaluation period), the Safety Review Committee (SRC) will review the available safety data and determine whether dose escalation to the next cohort may proceed.

The planned dose levels of BYT-1007 are 5 mg/day, 10 mg/day, 15 mg/day, and 25 mg/day, with 40 mg/day as an optional dose. The actual dose escalation may be modified based on safety findings and recommendations from the Safety Review Committee (SRC).

BYT-1007 will be administered orally as capsules.

The planned treatment duration is one 28-day cycle, with up to three additional 28-day cycles permitted at the Investigator's discretion.

Treatment adherence will be monitored through direct administration and observation during the mandatory hospitalization period (Day 1 to Day 7), together with study drug accountability records, dosing records, and returned unused study medication (if applicable).

---
Part B (BYT-1007 + venetoclax combination therapy)

Part B will commence after the maximum tolerated dose (MTD) of BYT-1007 monotherapy has been determined and reviewed by the Safety Review Committee (SRC).

Participants enrolled in Part A may be eligible for enrolment into Part B if they meet all Part B eligibility criteria and provide informed consent. Participants will be enrolled sequentially into the currently open dose cohort according to the study dose-escalation scheme.

The starting dose of BYT-1007 in Part B will be one dose level below the maximum tolerated dose (MTD) established during Part A. The maximum dose level evaluated will not exceed the MTD established in Part A and is expected to be no higher than 40 mg/day.

The dose of venetoclax will be fixed at its recommended dosage for AML (Days 1-3 of Cycle 1: 100-200-400 mg/day dose ramp-up; Cycle 1 Day 4 and beyond: 400 mg/day).

BYT-1007 will be administered orally as capsules, and venetoclax will be administered orally as tablets.

The planned treatment duration is one 28-day cycle, with up to three additional 28-day cycles permitted at the Investigator's discretion.

Treatment adherence will be monitored through inpatient administration during the mandatory hospitalization period (Day 1 to Day 7), study drug accountability records, dosing records, and returned unused study medication (if applicable).

Intervention code [1] 334086 0
Treatment: Drugs
Description of the comparator or control
There is no comparator or control.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345968 0
Maximum tolerated dose (MTD) of BYT-1007 monotherapy (Part A).
Timepoint [1] 345968 0
End of Cycle 1 (Day 28).
Primary outcome [2] 345969 0
Safety profile of BYT-1007 monotherapy (Part A).
Timepoint [2] 345969 0
From the first dose of study treatment until the end of treatment.
Primary outcome [3] 345970 0
Composite primary outcome: Maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and safety profile of BYT-1007 in combination with venetoclax (Part B).
Timepoint [3] 345970 0
MTD: End of Cycle 1 (Day 28). RP2D: Following review of the available Part B safety data by the Safety Review Committee (SRC). Safety: From the first dose of study treatment until completion of the 28-day safety follow-up after the end of treatment.
Secondary outcome [1] 463974 0
PK of BYT-1007 as monotherapy
Timepoint [1] 463974 0
Blood samples will be collected immediately before dosing (0 hour), and at 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing on Day 1; pre-dose on Day 2; and at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, and 48 hours after dosing on Day 5.
Secondary outcome [2] 463975 0
PK of BYT-1007 in combination with venetoclax
Timepoint [2] 463975 0
Blood samples will be collected immediately before dosing (0 hour), and at 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours after dosing on Day 1; pre-dose on Day 2; and at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, and 48 hours after dosing on Day 5.
Secondary outcome [3] 463976 0
PD of BYT-1007 as monotherapy
Timepoint [3] 463976 0
Day 1 (pre-dose); Day 2 (pre-dose); and Day 5 (24 hours post dose).
Secondary outcome [4] 463977 0
PD of BYT-1007 in combination with venetoclax
Timepoint [4] 463977 0
Day 1 (pre-dose); Day 2 (pre-dose); and Day 5 (24 hours post dose).

Eligibility
Key inclusion criteria
An eligible participant must fulfill all of the following inclusion criteria:
1. Participants with one of the following histologically/cytologically confirmed hematologic malignancies:
Part A:
ALL in relapsed/refractory status
Primary or secondary AML in relapsed/refractory status
Primary or secondary HR-MDS according to IPSS/IPSS-R/IPSS-M criteria in relapsed/refractory status
Any above-mentioned hematologic malignancy in treatment-naïve status but not eligible for intensive induction chemotherapies due to age or lack of fitness (prior hydroxyurea treatment is allowed)

Part B:
primary or secondary AML in relapsed/refractory status or in treatment-naïve status
but not eligible for intensive induction chemotherapies

2. Adequate renal and hepatic function, defined as
Estimated creatinine clearance of at least 30 mL/min, calculated using the Cockcroft-Gault formula or measured by 24-hour urine collection.
Serum bilirubin no greater than 1.5 times the upper limit of normal (ULN). Serum bilirubin no greater than 3.0 times the upper limit of normal (ULN) for treatment-naïve participants between 18 to 74 years of age.
Aspartate transaminase (AST) and alanine transaminase (ALT) no greater than 3.0 times the upper limit of normal (ULN).
3. White blood cell count less than 25 billion cells/L (hydroxyurea administration or leukapheresis is permitted to meet this criterion).
4. ECOG Performance Status
0 to 2
OR
2 to 3 for treatment naïve participants between 18 to 74 years of age
5. Women of childbearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use protocol specified highly effective contraceptive methods from Cycle 1 Day 1 through at least 180 days after the last dose of study drug, and must have a negative serum pregnancy test within 2 weeks prior to Cycle 1 Day 1
6. Sexually active male must agree to practice protocol-specified methods of contraception and refrain from sperm donation from Cycle 1 Day 1 through at least 180 days after the last dose of study drug.
7. Must be able and willing to give written informed consent.
Minimum age
18 Years
Maximum age
74 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Any patient who has any of the following exclusion criteria:
1. Acute promyelocytic leukemia
2. CNS involvement
3. Life expectancy <12 weeks
4. Having received major surgical procedures or investigational products within 4 weeks, or anticancer therapies within 2 weeks (prior hydroxyurea treatment is allowed)
5. Currently participating in other clinical studies
6. Known HIV infection
7. Known active HBV/HCV infection. Inactive hepatitis carrier status or low viral hepatitis
titer (HBV viral DNA < 2,000 IU/mL; HCV viral RNA< 50 genome equivalents/mL) on
antivirals (non-exclusionary medications) are not excluded.
8. Concurrent history of active malignancy in past two years, with the exception of
Adequately treated in situ carcinoma of the cervix uteri or breast;
Basal cell or localized squamous cell carcinoma of the skin;
Previous malignancy confined and surgically resected (or treated with other
modalities) with curative intent.
9. Concurrent severe and/or uncontrolled medical condition (e.g., uncontrolled diabetes, infection, hypertension, pulmonary disease), which in the Investigator's opinion could compromise the patient's safety
10. Swallowing difficulties or other condition that precludes oral route of administration
11. Being allergic to the active ingredient or any excipient of BYT-1007 or (Part B only)
venetoclax
12. Previous treatment with clofarabine or (Part B only) venetoclax
13. Received prohibited medication/food within the specified timeframe prior to Cycle 1 Day 1
14. Pregnant or lactating females
15. Unwilling or not capable of using effective means of contraception

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis
Descriptive statistics will be applied for the primary endpoint, secondary endpoints, patients’ demographic variables and adverse events. The number of observation, mean, median, standard deviation, range (minimum and maximum), and 95% confidence interval (CI) will be presented for continuous variables. For categorical variables, frequencies and proportions will be provided.
For PK analysis, the following parameters will be provided in descriptive statistics: Cmax, Tmax, AUC0- 24, and t1/2.
For PD analysis, the intracellular clofarabine triphosphate concentration will be provided in descriptive statistics.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321877 0
Commercial sector/Industry
Name [1] 321877 0
Boyen Therapeutics Australia Pty Ltd
Country [1] 321877 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Boyen Therapeutics Australia Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 324740 0
None
Name [1] 324740 0
Address [1] 324740 0
Country [1] 324740 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320415 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320415 0
Ethics committee country [1] 320415 0
Australia
Date submitted for ethics approval [1] 320415 0
19/06/2026
Approval date [1] 320415 0
Ethics approval number [1] 320415 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150410 0
A/Prof Dr Shaun Alan Fleming
Address 150410 0
Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004
Country 150410 0
Australia
Phone 150410 0
+61 390763583
Fax 150410 0
Email 150410 0
Contact person for public queries
Name 150411 0
Dr Shaun Alan Fleming
Address 150411 0
Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004
Country 150411 0
Australia
Phone 150411 0
+61 390763583
Fax 150411 0
Email 150411 0
Contact person for scientific queries
Name 150412 0
Dr Shaun Alan Fleming
Address 150412 0
Alfred Hospital, 55 Commercial Road, Melbourne, VIC 3004.
Country 150412 0
Australia
Phone 150412 0
+61 390763583
Fax 150412 0
Email 150412 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.